ACADIA Pharmaceuticals (NASDAQ:ACAD) Insider James Kihara Sells 5,401 Shares of Stock

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) insider James Kihara sold 5,401 shares of the business’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $21.18, for a total value of $114,393.18. Following the completion of the sale, the insider directly owned 24,509 shares in the company, valued at $519,100.62. This trade represents a 18.06% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

James Kihara also recently made the following trade(s):

• On Monday, May 4th, James Kihara sold 1,332 shares of ACADIA Pharmaceuticals stock. The stock was sold at an average price of $21.79, for a total value of $29,024.28.
• On Tuesday, April 7th, James Kihara sold 1,030 shares of ACADIA Pharmaceuticals stock. The stock was sold at an average price of $22.20, for a total value of $22,866.00.

ACADIA Pharmaceuticals Trading Down 0.3%

ACADIA Pharmaceuticals stock opened at $21.19 on Thursday. The business’s fifty day simple moving average is $21.69 and its two-hundred day simple moving average is $23.83. ACADIA Pharmaceuticals Inc. has a 12 month low of $19.69 and a 12 month high of $28.35. The company has a market capitalization of $3.63 billion, a price-to-earnings ratio of 9.63, a price-to-earnings-growth ratio of 25.74 and a beta of 0.86.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.04 by ($0.02). ACADIA Pharmaceuticals had a return on equity of 9.61% and a net margin of 34.30%.The company had revenue of $268.10 million during the quarter, compared to the consensus estimate of $280.25 million. During the same period last year, the firm posted $0.11 earnings per share. The company’s revenue was up 9.7% compared to the same quarter last year. On average, equities research analysts predict that ACADIA Pharmaceuticals Inc. will post 0.39 EPS for the current year.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. TD Cowen boosted their price target on ACADIA Pharmaceuticals from $35.00 to $37.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Mizuho upgraded ACADIA Pharmaceuticals from a “neutral” rating to an “outperform” rating and boosted their price target for the stock from $29.00 to $35.00 in a research note on Monday, February 23rd. Weiss Ratings cut ACADIA Pharmaceuticals from a “hold (c+)” rating to a “hold (c)” rating in a research note on Friday, May 1st. Wolfe Research assumed coverage on ACADIA Pharmaceuticals in a research note on Monday, February 23rd. They issued an “outperform” rating and a $33.00 price target for the company. Finally, Oppenheimer restated a “market perform” rating on shares of ACADIA Pharmaceuticals in a research note on Friday, February 6th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $31.63.

Institutional Trading of ACADIA Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the company. State Street Corp increased its position in ACADIA Pharmaceuticals by 9.0% during the fourth quarter. State Street Corp now owns 7,910,733 shares of the biopharmaceutical company’s stock valued at $211,296,000 after acquiring an additional 655,257 shares during the last quarter. First Trust Advisors LP increased its position in ACADIA Pharmaceuticals by 47.3% during the first quarter. First Trust Advisors LP now owns 3,343,868 shares of the biopharmaceutical company’s stock valued at $74,435,000 after acquiring an additional 1,073,834 shares during the last quarter. Geode Capital Management LLC increased its position in ACADIA Pharmaceuticals by 3.4% during the fourth quarter. Geode Capital Management LLC now owns 3,239,451 shares of the biopharmaceutical company’s stock valued at $86,539,000 after acquiring an additional 106,807 shares during the last quarter. Dimensional Fund Advisors LP increased its position in ACADIA Pharmaceuticals by 8.0% during the first quarter. Dimensional Fund Advisors LP now owns 3,155,160 shares of the biopharmaceutical company’s stock valued at $70,222,000 after acquiring an additional 234,186 shares during the last quarter. Finally, Braidwell LP purchased a new stake in ACADIA Pharmaceuticals during the third quarter valued at $50,760,000. Hedge funds and other institutional investors own 96.71% of the company’s stock.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.